{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:28:31Z","timestamp":1784629711072,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prro.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:44:41Z","timestamp":1758602681000},"page":"e581-e596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Outcome of Stereotactically Designed Hypofractionated Image Guided Radiation Therapy in Large, Unresectable Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-8908","authenticated-orcid":false,"given":"Natalie Sean Man","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ann Shing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus Wan Yan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Sik-Kwan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Sin","family":"Yu Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie Hoi Man","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie Wing Ling","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith Wan Hang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Ka Heng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Chi Sing","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming (Spring)","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Leung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.05.016_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2025.05.016_bib0002","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2025.05.016_bib0003","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1445-2197.2012.06079.x","article-title":"Surgical treatment for large hepatocellular carcinoma: Does size matter?","volume":"82","author":"Tsoulfas","year":"2012","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.prro.2025.05.016_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjsurg.2008.09.019","article-title":"Outcome after curative resection for a huge (\u226510 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification","volume":"198","author":"Choi","year":"2009","journal-title":"Am J Surg"},{"key":"10.1016\/j.prro.2025.05.016_bib0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.12809\/hkjr2017152","article-title":"Prognostic factors and survival in advanced large hepatocellular carcinomas treated with combined transarterial chemoembolisation and hypofractionated image-guided radiotherapy","volume":"23","author":"Wong","year":"2020","journal-title":"Hong Kong J. Radiol"},{"key":"10.1016\/j.prro.2025.05.016_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0007","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.prro.2025.05.016_bib0008","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1478-3231.2005.01170.x","article-title":"Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma","volume":"25","author":"Shim","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.prro.2025.05.016_bib0009","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.prro.2025.05.016_bib0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/hep.1840110516","article-title":"Long-term results of resection for large hepatocellular carcinoma: A multivariate analysis of clinicopathological features","volume":"11","author":"Lai","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.prro.2025.05.016_bib0011","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0012","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12094-010-0492-x","article-title":"Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma","volume":"12","author":"C\u00e1rdenes","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0013","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0014","doi-asserted-by":"crossref","first-page":"E169","DOI":"10.1016\/j.ijrobp.2015.07.984","article-title":"Potential benefits of fractionation over SBRT for large liver tumors","volume":"93","author":"Dow","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0016","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejso.2015.05.023","article-title":"Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization","volume":"41","author":"Ciria","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","author":"Schefter","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0018","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1118\/1.3476463","article-title":"Real-time monitoring and control on deep inspiration breath-hold for lung cancer radiotherapy-combination of ABC and external marker tracking","volume":"37","author":"Wong","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0019","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00066-018-1391-2","article-title":"Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B\u2013C hepatocellular carcinoma","volume":"195","author":"Chiang","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2025.05.016_bib0020","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-Associated Liver Injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0360-3016(03)00434-6","article-title":"Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma","volume":"57","author":"Yamada","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.prro.2025.05.016_bib0024","unstructured":"Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE). v.5.0 [5\u00d77]. Cancer Therapy Evaluation Program (CTEP) Resources for Clinical Trials in NCI Networks. 2017. Accessed May 17, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development#ctcae-and-ctep-codes."},{"key":"10.1016\/j.prro.2025.05.016_bib0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0026","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.prro.2017.10.013","article-title":"Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints","volume":"8","author":"Chapman","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.prro.2025.05.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052294","article-title":"RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.prro.2025.05.016_bib0029","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.05.016_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0031","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.05.016_bib0032","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.016_bib0033","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41598-020-58108-1","article-title":"Palliative liver radiotherapy (RT) for symptomatic hepatocellular carcinoma (HCC)","volume":"10","author":"Yeung","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.prro.2025.05.016_bib0034","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1200\/JCO.2013.49.9202","article-title":"Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases","volume":"31","author":"Soliman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0035","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0036","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00066-021-01879-x","article-title":"Presence of tumour capsule on contrast-enhanced CT is associated with improved outcomes of stereotactic body radiation therapy in hepatocellular carcinoma patients","volume":"198","author":"Mak","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2025.05.016_bib0037","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2025.05.016_bib0038","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.prro.2025.05.016_bib0039","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.etp.2009.02.114","article-title":"Hepatocyte regeneration after partial liver irradiation in rats","volume":"61","author":"Zhao","year":"2009","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.prro.2025.05.016_bib0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): A single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2025.05.016_bib0041","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/hpb.12331","article-title":"Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of \u22653 cm","volume":"17","author":"Jacob","year":"2015","journal-title":"HPB"},{"key":"10.1016\/j.prro.2025.05.016_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00066-015-0929-9","article-title":"Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas","volume":"192","author":"Chan","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2025.05.016_bib0043","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.suronc.2019.01.006","article-title":"Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis","volume":"28","author":"Wong","year":"2019","journal-title":"Surg Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0044","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinre.2016.04.006","article-title":"Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Zeng","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.prro.2025.05.016_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijrobp.2022.05.021","article-title":"Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: Results from a prospective phase 2 trial","volume":"114","author":"Buckstein","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0046","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ijrobp.2008.06.1486","article-title":"The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma","volume":"73","author":"Huang","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.016_bib0047","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/0284186X.2013.820342","article-title":"Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients","volume":"53","author":"Sanuki","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0048","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.016_bib0049","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 Microspheres: A comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025002012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025002012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:44:37Z","timestamp":1761900277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025002012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1879850025002012"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.016","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcome of Stereotactically Designed Hypofractionated Image Guided Radiation Therapy in Large, Unresectable Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}